BFRI vs. TPST, TENX, CARA, NRSN, CYTH, GDTC, NNVC, QTTB, MIRA, and RLMD
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Tempest Therapeutics (TPST), Tenax Therapeutics (TENX), Cara Therapeutics (CARA), NeuroSense Therapeutics (NRSN), Cyclo Therapeutics (CYTH), CytoMed Therapeutics (GDTC), NanoViricides (NNVC), Q32 Bio (QTTB), MIRA Pharmaceuticals (MIRA), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.
Biofrontera vs. Its Competitors
Biofrontera (NASDAQ:BFRI) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Biofrontera currently has a consensus target price of $2.75, suggesting a potential upside of 329.69%. Tempest Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 353.51%. Given Tempest Therapeutics' higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than Biofrontera.
In the previous week, Tempest Therapeutics had 3 more articles in the media than Biofrontera. MarketBeat recorded 6 mentions for Tempest Therapeutics and 3 mentions for Biofrontera. Tempest Therapeutics' average media sentiment score of 0.80 beat Biofrontera's score of 0.30 indicating that Tempest Therapeutics is being referred to more favorably in the news media.
Biofrontera has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2, indicating that its share price is 300% less volatile than the S&P 500.
Biofrontera has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Tempest Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Tempest Therapeutics' return on equity of -187.44% beat Biofrontera's return on equity.
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 1.2% of Biofrontera shares are owned by company insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Tempest Therapeutics received 93 more outperform votes than Biofrontera when rated by MarketBeat users. However, 69.23% of users gave Biofrontera an outperform vote while only 64.56% of users gave Tempest Therapeutics an outperform vote.
Summary
Tempest Therapeutics beats Biofrontera on 10 of the 17 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
This page (NASDAQ:BFRI) was last updated on 6/13/2025 by MarketBeat.com Staff
